Medical Information
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

LYRICA® CR, CV Principal Display Panel (pregabalin extended-release)

PRINCIPAL DISPLAY PANEL - 82.5 mg Tablet Bottle Label

Pfizer
NDC 0071-1026-01

Lyrica® CR
(pregabalin)
extended release tablets

CV

82.5 mg

ALWAYS DISPENSE WITH
MEDICATION GUIDE

30 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 82.5 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 165 mg Tablet Bottle Label

Pfizer
NDC 0071-1027-01

Lyrica® CR
(pregabalin)
extended release tablets

CV

165 mg

ALWAYS DISPENSE WITH
MEDICATION GUIDE

30 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 165 mg Tablet Bottle Label

PRINCIPAL DISPLAY PANEL - 330 mg Tablet Bottle Label

Pfizer
NDC 0071-1029-01

Lyrica® CR
(pregabalin)
extended release tablets

CV

330 mg

ALWAYS DISPENSE WITH
MEDICATION GUIDE

30 Tablets
Rx only

PRINCIPAL DISPLAY PANEL - 330 mg Tablet Bottle Label
Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event